“…The barriers may include delays in CCA diagnosis, hurdles associated with tissue acquisition for biomarker testing, ineffective collaboration between the hepatobiliary multidisciplinary team (MDT), and lack of awareness of the importance of biomarker testing [ 14 , 15 , 16 , 17 , 18 ]. The integral role of an effective MDT for the diagnosis and optimal treatment of patients with cancer, including CCA, is essential in both the community and academic settings; however, challenges associated with optimal patient care remain, which highlight the need for improvement [ 19 , 20 , 21 , 22 , 23 ]. In particular, patients with metastatic CCA progress rapidly; thus, improved diagnosis, biomarker testing, and treatment options are needed in this setting.…”